AGArun Gurunathan

Arun Gurunathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arun Gurunathan has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    American Society for Transplantation and Cellular Therapy Series: #5—Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients

    by Carolyn D. Alonso, Gabriela Maron, Mini Kamboj, Paul A. Carpenter, Arun Gurunathan, Kathleen M. Mullane, Erik R. Dubberke


  • Open Access

    Publisher Correction: MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia

    by Svetlana S. Itskovich, Arun Gurunathan, Jason Clark, Matthew Burwinkel, Mark Wunderlich, Mikaela R. Berger, Aishwarya Kulkarni, Kashish Chetal, Meenakshi Venkatasubramanian, Nathan Salomonis, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

  • Open Access

    MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia

    by Svetlana S. Itskovich, Arun Gurunathan, Jason Clark, Matthew Burwinkel, Mark Wunderlich, Mikaela R. Berger, Aishwarya Kulkarni, Kashish Chetal, Meenakshi Venkatasubramanian, Nathan Salomonis, et al.

    Despite growing awareness of the biologic features underlying MLL-rearranged leukemia, targeted therapies for this leukemia have remained elusive and clinical outcomes remain dismal. MBNL1, a protein involved in alternative splicing, is consistently overexpressed in MLL-rearranged leukemias. We found that MBNL1 loss significantly impairs propagation of murine and human MLL-rearranged leukemia in vitro and in vivo. Through transcriptomic profiling of our experimental systems, we show that in leukemic cells, MBNL1 regulates alternative splicing (predominantly intron exclusion) of several genes including those essential for MLL-rearranged leukemogenesis, such as DOT1L and SETD1A. We finally show that selective leukemic cell death is achievable with a small molecule inhibitor of MBNL1. These findings provide the basis for a new therapeutic target in MLL-rearranged leukemia and act as further validation of a burgeoning paradigm in targeted therapy, namely the disruption of cancer-specific splicing programs through the targeting of selectively essential RNA binding proteins.


  • Impact of vascular anomalies on the PTEN phenotype in children and young adults

    by Arun Gurunathan, Kiersten Ricci, Ionela Iacobas, Surya P. Rednam, Katie Wusik, Lin Fei, Adrienne M. Hammilll

    Germline PTEN (phosphatase and tensin homolog) mutations lead to inappropriate cell survival and growth, and a predisposition to multiple cancers. Some patients also have vascular anomalies (VAs), and it is unclear whether these patients have different phenotypes or oncologic risks. We conducted a two‐institution retrospective cohort study to better understand the phenotypes of children and young adults with PTEN mutations, and to compare individuals with VA to those without. Almost half of the patients had thyroid tumors and nearly one quarter developed gastrointestinal tumors before 30 years of age. The presence of VA was positively associated with bulky overgrowth but did not appear to modify oncologic risk.


  • Limitations of HLH‐2004 criteria in distinguishing malignancy‐associated hemophagocytic lymphohistiocytosis

    by Arun Gurunathan, Alexander A. Boucher, Melissa Mark, Kristina M. Prus, Maureen M. O'BRien, Erin H. Breese, Benjamin E. Mizukawa, Michael J. Absalon, Adam S. Nelson, Michael B. Jordan, et al.

    Hemophagocytic lymphohistiocytosis (HLH) is characterized by dysregulated immune activation. Primary HLH involves hereditary deficits in cytotoxic lymphocytes while secondary HLH is triggered by extrinsic factors. The HLH‐2004 criteria are widely used for clinical diagnosis, yet their specificity for HLH or their ability to differentiate primary from secondary disease is unclear, potentially leading to inappropriate treatment. We describe several cases where fulfillment of HLH‐2004 criteria obscured the diagnoses of underlying malignancies and delayed curative management. These issues are remedied without waiting for genetic testing results through an alternative diagnostic approach using flow cytometry–based immunologic assays and a thorough investigation for malignancy.


  • Significance of CNS 2 cerebrospinal fluid status post‐induction in pediatric and adolescent patients with acute lymphoblastic leukemia

    by Arun Gurunathan, Ami V. Desai, L. Charles Bailey, Yimei Li, John K. Choi, Susan R. Rheingold

    Background: At diagnosis, there are prognostic implications of low‐level leukemic blasts (CNS 2) in the cerebrospinal fluid (CSF) of patients with acute lymphoblastic leukemia (ALL). However, the significance of post‐induction CNS 2 results and the impact of equipment on CNS 2 prevalence have not been well studied.Procedure: A single‐institution retrospective cohort study was conducted to analyze the outcome of patients with ≥1 post‐induction CNS 2. A subanalysis compared the proportion of CNS 2 CSF results using 2 different cytocentrifuges; the Shandon Cytospin used from 2005 to 2008 and the Wescor Cytopro used from 2010 to 2014.Results: Over 4500 post‐induction CSF samples were analyzed, of which 59 were CNS 2. In covariate‐adjusted analyses, post‐induction CNS 2 did not significantly increase relapse risk. The proportion of CNS 2 results increased 4.3‐fold in noninfants and 6.3‐fold in infants using the Wescor Cytopro. Cytocentrifuge machine did not affect CNS 3 prevalence.Conclusions: These findings support our current practice of not changing management based on a post‐induction CNS 2 CSF and highlight how equipment changes can significantly influence testing results. More data are needed to analyze relapse by subpopulations, such as those with repeated CNS 2 findings.


  • Mucositis and Pain in the Peri-HSCT Period

    by Arun Gurunathan, Neil S. Patel, Jason L. Freedman


  • Nutrition in the Peri-HSCT Period

    by Arun Gurunathan, Judy Bailer, Jason L. Freedman

  • Behcet Disease Initially Presenting as Deep Venous Thrombosis: A Case Report

    by Arun Gurunathan, David T. Teachey, Kudakwashe R. Chikwava, Char Witmer, Ami V. Desai

    Behcet disease is a potentially life-threatening multisystemic vasculitis with thrombotic tendency. Mucocutaneous ulcers, arthritis, and uveitis are the most recognizable features, but may be absent at the time of medical evaluation. We report a case in which a 8-year old patient presented with spontaneous bilateral lower extremity deep venous thromboses, and screening for rheumatologic symptoms led to diagnosing Behcet. This case demonstrates that deep venous thromboses can be the initial event bringing a patient with Behcet to medical attention, highlighting the importance of screening for underlying rheumatologic diseases in pediatric patients who present with unprovoked thrombosis.


  • Molecular signatures and responses to targeted therapies in over 300 relapsed and therapy-refractory young adult (AYA) and childhood cancers.

    by Erin Haag Breese, Brian Turpin, Phillip Dexheimer, Benjamin Mizukawa, Laura Agresta, Arun Gurunathan, Thomas Pfeiffer, Jeremy Rubinstein, Luke Smart, Garrett Michael Frampton, et al.

    11514 Background: Contemporary chemotherapy-based regimens provide cures for most pediatric & AYA cancers. However, for patients with relapsed/refractory malignancies, outcomes are poor & imply a distinct and aggressive biology. Identifying common themes in the molecular architecture & oncogenic mechanisms in these patients is a critical priority for drug development. We hypothesized that the molecular signature of cancers in these patients would be independent of histology. We also assessed the response to molecular alteration (MA)-targeted therapies. Methods: IRB-approved analysis of MAs in 306 relapsed/refractory pediatric & AYA malignancies (116 hematologic malignancies, 68 sarcomas, 46 neuroblastomas, 36 CNS, 14 liver, 9 renal, 17 other) was performed. DNA was analyzed for MAs (Foundation Medicine, Cambridge, MA; Univ of Washington, Seattle, WA); additional MAs were identified by cytogenetic & fluorescent in situ hybridization analyses. Results: Median age was 8 years (range birth - 44 yrs). MAs were identified in 90.1% of patients & included a median of 2 mutations (range 0-18) in 133 cancer-related genes. In contrast to genomic analyses of de novo malignancies in children, a high frequency of TP53 MAs was identified (20.4% of patients) and was associated with inferior survival. MAs were identified in targetable pathways including cell cycle regulation (32.6%), DNA repair (7.2%), epigenetic (28.6%), RAS/RAF/MEK (24%), tyrosine kinase (TK; 18.4%), PI3K/AKT/mTOR (11.8%), and NOTCH/WNT (8.9%). A higher number of MAs was associated with inferior survival. Patients with alterations in epigenetic & TK pathways also had inferior outcomes. MAs were frequently independent of histology & the spectrum of mutations was similar to adult cancers. Exceptional responses were observed with MA-based assignment of therapies (epigenetic, NTRK, RAS/RAF/MEK & ALK). Conclusions: Relapsed/refractory pediatric & AYA cancers have frequent MAs independent of histology. The spectrum of MAs is distinct from de novo disease & potentially reflects tumor evolution & resistance mechanisms. These findings support MA-guided approaches to new drug development paired with adult trials.